In a new subsector report presented at the Northeast MedTech Summit in Boston, which was organized by SVB, SVB analyzed the investment and M&A activity of private, venture-backed medtech companies. Investment is poised to surpass 2016 levels, driven in part by two recent developments: monitoring devices that help expand care beyond traditional healthcare settings and advancements in neuromodulation.
Here are some additional insights you’ll glean from the subsector report:
- Device investing in 2017 is on track to surpass 2016, approaching its historical share of overall invested venture dollars
- Early-stage medtech investing in 2017 is set to exceed 2016 in both the number of deals and the number of dollars invested
- Corporate venture funds continue to play a central role in the landscape of medtech investors, with increasing participation from private equity firms and family offices
- Strong investment in medtech technologies based on artificial intelligence and robotics suggests that the sector is poised to have a transformational impact on healthcare
- The M&A environment for medtech remains robust, and the difference in exit multiples in favor of premarket approval and de novo 510(k) regulatory pathways continues